A recent study has found that insulin treatment is not responsible for the poorer health outcomes after stenting in patients with type 2 diabetes. However, it was suggested that everolimus-eluting stents might be a better choice for patients using insulin.
Researchers found that after adjusting for certain risks, insulin-treated type 2 diabetes patients who underwent stenting did not experience an increased rate of combined cardiac death, target vessel revascularization, or target vessel myocardial infarction when compared to patients taking other types of anti-diabetes medications.
The findings were based on the health outcomes of over 1,800 patients and suggested that the increased possibility of cardiovascular events among patients treated with insulin might actually be due to differences in baseline risk factors as well as disease control and duration.
These findings were published in JAMA Cardiology on April 20, 2016.